Modality
Cell Therapy
MOA
TNFi
Target
GPRC5D
Pathway
Proteasome
Bladder Ca
Development Pipeline
Preclinical
~Apr 2021
→ ~Jul 2022
Phase 1
Oct 2022
→ Apr 2029
Phase 1Current
NCT06348752
837 pts·Bladder Ca
2022-10→2029-04·Not yet recruiting
837 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-113.0y awayInterim· Bladder Ca
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1
Not yet…
Catalysts
Interim
2029-04-11 · 3.0y away
Bladder Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06348752 | Phase 1 | Bladder Ca | Not yet recr... | 837 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D |